Company: EVGN
Filing Date: 2025-09-30
Form Type: POS AM
Source: 0001178913-25-003429
Chunk: 1

Company: Evogene Ltd.
Filing Date: 2025-09-30
Form: POS AM
Chunk 1
---
”) that are issuable upon exercise of 3,384,616 ordinary warrants (the “ordinary warrants”) held by the Selling Shareholder. This post-effective amendment No. 2 to the Registration Statement (the “Post-Effective Amendment”) is being filed pursuant to Section 10(a)(3) of the Securities Act of 1933, as amended, to update the Registration Statement in order to include, in the Registration Statement, the Company’s unaudited consolidated financial statements and the notes thereto as of, and for the six-month period ended June 30, 2025, and certain other updated information. No additional securities are being registered under this Post-Effective Amendment. This Post-Effective Amendment only covers the sale of the ordinary shares underlying the ordinary warrants by the Selling Shareholder from time to time. All registration fees payable in connection with the registration of the sale of the ordinary shares by the Selling Shareholder were previously paid in connection with the initial filing of the Registration Statement. The information in this preliminary prospectus is not complete and may be changed. The selling shareholder identified herein may not sell these securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED SEPTEMBER 30, 2025 EVOGENE LTD. 3,384,616 Ordinary Shares
Offered by the Selling Shareholder This prospectus relates to the resale, from time to time, by the selling shareholder named herein, or the Selling Shareholder, or its pledgees, donees, transferees, or other successors in interest, of up to 3,384,616 of our ordinary shares, par value 0.2 New Israeli Shekels, or NIS, per share, or ordinary shares, that are issuable upon exercise of 3,384,616 ordinary warrants, or the ordinary warrants, held by the Selling Shareholder. The ordinary warrants held by the Selling Shareholder were sold to it by our company in a private placement that was completed on August 26, 2024 pursuant to that certain securities purchase agreement, dated as of August 23, 2024, or the Securities Purchase Agreement, by and between our company and the Selling Shareholder. Pursuant to that private placement, we sold to the